Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5190267 | 1.00 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27702796 | 1.00 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816703 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824865 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13985878 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824868 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4175650 | 0.82 | TUBB4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4821107 | 0.80 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4826205 | 0.80 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4826199 | 0.80 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION | 2009-02-12 | — | — | US | disclosed |
| US-7468446-B2 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1794139-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006028963-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | NQO1, LTC4S, VHL | PDE4A 1046/4885PDE4B 798/4885PDE4C 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.